UNIVERSAL-PEACE-FED
5.8.2020 12:44:12 CEST | Business Wire | Press release
(Sunday August 9th, 3 am CET)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005488/en/
More than 1 Million are expected to join! World Leaders to point the way forward beyond global challenges including Covid-19, race relations, environmental problems and global economic turndown. Speakers include former UN Secretary-General Ban Ki-moon and H.E. Macky Sall, President of Senegal. UPF Co-Founder Dr. Hak Ja Han will offer a special keynote message of hope to humanity.
Registration link for online participants:
World Leaders to Address “Rally of Hope”
Despite material advances and the amassing of unprecedented wealth, serious global problems remain unsolved. This is all the more striking when it is seen alongside worldwide efforts to maintain peace, resolve conflicts and end poverty by major international peace-keeping bodies, public and private.
Territorial disputes, religious and racial discord, the collapse of family values, and an aggregate of environmental issues are flaring up on all continents. Added to this is the COVID-19 pandemic which has caused catastrophic economic debt. It seems like a perfect storm.
Just such dilemmas drew the late Rev. Dr. Sun Myung Moon and his wife Dr. Hak Ja Han Moon to speak out for the realization of an ideal world. Their vision: one human family bound together by the love of God. For decades, they have advocated the philosophy of interdependence, mutual prosperity, and universal values which challenges us with the novel concept of seeing our own purpose in life fulfilled in the well-being of others.
To emphasize these values and help address related problems, the Universal Peace Federation (an NGO in general consultative status with the Economic and Social Council of the United Nations), will be hosting the latest in a series of on-line virtual summits. The Rally of Hope will be held August 9, 2020 beginning at 9:40 AM (Korean time). The official theme is, “One Million Rally of Hope for the Realization of a Heavenly Unified World of Interdependence, Mutual Prosperity, and Universal Values.”
“The goal of these assemblies is to set a cornerstone for the realization of a world of proactive international and interreligious collaboration for the good of all people,” said Dr. Thomas G. Walsh, Chairman of the Universal Peace Federation.
Ban Ki-moon, former UN Secretary-General, will give the welcome address. Congratulatory messages presented by international dignitaries will follow. Interspersed with first-class entertainment, keynote addresses will be given by H.E. Hun Sen, Prime Minister of Cambodia; H.E. Macky Sall, President of Senegal; the Hon. Brigi Rafini, Prime Minister of Niger and other world leaders.
Finally, Dr. Hak Ja Han Moon, co-founder of the Universal Peace Federation and host of the Rally, will give her keynote address.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005488/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom